weight gain after tirzepatide Before and loss results: what real transformations look like and what determines success Weight-loss drug results in the

Demand for Zepbound and Mounjaro has been so hot that Eli Lilly has struggled to make enough, leading the FDA to place it on a list of drugs in shortage and enabling compounding pharmacies to make cheaper, off-brand copies of it

Overusing injections or receiving them too frequently without medical supervision may not provide additional benefits and could increase the risk of side effects

For the latest market situation, check manufacturer communications, national formularies, or drug shortage lists

Over 12 months, lixisenatide produced a modest 3-point improvement on a 132-point motor disability scale compared with placebo, primarily due to deterioration in the placebo group